Pfizer reports data from Phase II multiple myeloma treatment trial [Yahoo! Finance]
Pfizer, Inc. (PFE)
Last pfizer, inc. earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.pfizer.com/investors-overview/default.aspx
Company Research
Source: Yahoo! Finance
ELREXFIO is a B-cell maturation antigen (BCMA)-cluster of differentiation (CD)3-directed bispecific antibody immunotherapy delivered subcutaneously. The non-randomised, open-label, multicentre trial assessed ELREXFIO monotherapy in patients who are refractory to a minimum of one proteasome inhibitor, immunomodulatory drug, and anti-cluster of differentiation 38 antibody. Two participant cohorts were evaluated, including those previously treated with BCMA-targeted therapies. The study's primary endpoint was the objective response rate (ORR), with key secondary outcomes including duration of response and safety. According to the findings, a median overall survival (OS) of 24.6 months was reported in cohort A of the single arm trial. The trial showcased an ORR of 61.0% and a complete response rate (CRR) of 37.4%, with a median duration of response not yet reached. At the two-year mark, the estimated duration of response rate stood at 66.9% for all responders, and 87.9% for t
Show less
Read more
Impact Snapshot
Event Time:
PFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PFE alerts
High impacting Pfizer, Inc. news events
Weekly update
A roundup of the hottest topics
PFE
News
- Pharma M&A: The top high value deals in 2023 [Yahoo! Finance]Yahoo! Finance
- Reminder: The Insidious Propaganda Campaign To Shame America Into Jabbing Up [zero hedge]zero hedge
- Pfizer (PFE) Stock Sinks As Market Gains: Here's Why [Yahoo! Finance]Yahoo! Finance
- Semafor Business Summit: Beware of the the mushy middle [Yahoo! Finance]Yahoo! Finance
- Wall Street Lunch: Pfizer Looks To Take Next Step In Weight-Loss Drugs [Seeking Alpha]Seeking Alpha
PFE
Earnings
- 5/1/24 - Beat
PFE
Sec Filings
- 6/17/24 - Form 4
- 6/17/24 - Form 4
- 6/11/24 - Form 11-K
- PFE's page on the SEC website